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ABSTRACT 
Monitoring the adherence of patients taking highly-active anti-retroviral 
therapy (HAART) and Pre-Exposure Prophylaxis (PrEP) is a key step in treating 
an HIV infection. For most regimens, when patients are not at least 95% adherent 
to their drug schedule there is a loss of effectiveness in treatment resulting in 
increases of health care costs, increases of the rate of transmission, and reduction 
of positive patient outcomes. Currently, subjective methods such as pill counting, 
electronic drug monitoring, and patient self-reporting are the only ways clinicians 
can track adherence and intervene in cases of non-compliance. We address this 
issue by developing colorimetric solutions to directly assay for the presence of 
common HIV drug metabolites in urine.   
First we developed a dipstick based point-of-care azide-alkyne click 
chemistry assay with colorimetric readout that directly tests for the presence of 
azidothymidine (AZT). An alkyne-modified dextran was synthesized and 
characterized by NMR and then used to colorimetrically report the presence of AZT 
in urine samples. The assay is specific to azide-containing molecules that are not 
vii 
 
naturally present in the urine and is sensitive to physiologically relevant urine 
concentrations as low as 750µM. Second we adapted the Wheeler and Johnson 
test, originally discovered for the determination of uracil and cytosine, for 
colorimetric readout of lamivudine (3TC) and emtricitabine (FTC). The cytosine 
base of these molecules is reacted with bromine and precipitated by barium 
hydroxide to give a purple color to the solution. The protocol was adapted to be 
performed easily with urine samples at physiological concentrations. Finally, an 
antibody-based lateral flow device has been designed for the detection of tenofovir 
(TFV). Direct application of urine to the lateral flow device gives fast, clear, and 
reliable readouts of TFV detection. All of these colorimetric assays, which can be 
done in resource-limited settings with minimal equipment, are all strong 
alternatives over current direct measurement techniques that are expensive and 
require trained users such as HPLC and NMR. In addition the detection of AZT 
and TFV can be deployed at the point-of-care for direct monitoring where the need 
is greatest. 
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Chapter 1: Introduction and Thesis Aims 
 
1.1 Overarching Goals and Thesis Aims 
The purpose of this thesis work was to develop colorimetric methods to 
monitor HIV drug metabolites in patient urine to monitor adherence to prescribed 
drug regimens. To achieve this we proposed three aims: 
 
Specific Aim 1: Develop a dipstick based point-of-care device for the 
detection of AZT in urine. 
We capitalized on the azide functional group of AZT to perform azide-alkyne 
cycloaddition with a modified dextran substrate on a dipstick platform. The 
completion of this reaction resulted in a visual color change of the dextran at 
clinically relevant concentrations. The assay was optimized for a clear readout at 
the point-of-care without the need for complex laboratory equipment. 
 
Specific Aim 2: Develop a colorimetric assay for the detection of 3TC and 
FTC in urine. 
We utilized a chemical assay that was originally developed for the detection 
of cytosine and uracil to colorimetrically detect 3TC and FTC in urine. The cytosine 
base of 3TC and FTC was reacted with bromine and barium hydroxide to form a 
purple precipitate that can be visualized from patient urine samples. Minor sample 
2 
 
preparation before the assay allowed us to improve the limit of detection to 
clinically relevant concentrations. 
 
Specific Aim 3: Develop a lateral flow device for the detection of TFV in urine. 
A TFV-sensitive antibody was raised and used to detect the presence of 
TFV in spiked urine samples using both a HRP-based competition assay and a 
gold nanoparticle-based lateral flow assay. The competitive assay relies on the 
extinction of chemiluminescent signal caused by the presence of TFV. The gold-
based assay relies on the aggregation of gold nanoparticles catalyzed by the 
presence of TFV on a simple lateral flow strip to allow for point-of-care monitoring 
of this important drug metabolite. 
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1.2 Introduction on HIV drug regimens 
Despite great advances in both diagnosis and treatment, the human 
immunodeficiency virus (HIV) remains a major global health problem. At the end 
of 2015 about 36.7 million people were living with HIV worldwide with over 25 
million cases located in sub-Saharan Africa where resources are limited and the 
treatment needs are great. Out of the globally infected population, 17 million were 
taking highly active antiretroviral treatments (HAART) to manage their infections1. 
ARV treatments have been used since the late 1980’s to effectively reduce the 
viral load of HIV patients. Today, worldwide, ARV treatments involve a cocktail of 
antiretroviral drugs that lower viral load, help limit the appearance of drug resistant 
strains, and help prevent initial infection when used for pre-exposure prophylaxis 
(PrEP). 
PrEP for HIV prevention is an important tool to limit the spread of the virus 
in high-risk populations who may be exposed. In July 2012, the FDA approved the 
use of Truvada, a combination pill containing tenofovir disoproxil fumarate (TDF) 
which is a soluble form of the drug which is metabolized to TFV and FTC, for PrEP. 
Studies have shown that using PrEP reduces the risk of HIV infection by 92% 
compared to those who do not take preventative medications2. 
Optimal treatment efficacy relies on patient adherence to HAART or PrEP 
of at least 95%3. For example, to properly reduce the risk of HIV infection PrEP 
must be taken every day and patients must follow up with their doctor every three 
months for adherence counseling2. Studies have shown, however, that many 
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patients do not adhere enough to HAART or PrEP without intervention. These non-
adhering patients show a distinct drop in virological suppression and increase in 
the risk of developing drug resistance4. However, when these patients were 
informed of their non-adherence by clinicians they modified their behavior and 
adherence in the following months increased to acceptable levels (between 95–
100% adherence)5. While a few modern regimens, especially those used in the 
U.S., are still effective around 80% adherence, most therapies require higher 
adherence, and all regimens are more efficacious when the dosage timings are 
followed completely. 
In addition to decreased efficacy there are many negative consequences to 
non-adherence of PrEP and HAART. Health care costs are increased due to the 
higher expense of second-line drug regimens and the treatment of sicker patients. 
Poor adherence habits often lead to the development of drug resistant HIV strains 
that are harder to treat and increase the risks involved in transmitting the disease 
to others. 
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1.3 Current Adherence Monitoring Techniques 
While monitoring adherence is such an important part of patient treatment, 
there are currently no direct ways to determine if the prescribed medication is being 
taken. In fact, the WHO stated in a 2013 report that in treating pregnant women 
with HIV to limit mother-to-child transmission of the disease “it is not possible to 
determine adherence to the regimen in most cases”6. The WHO named this one 
of the biggest weaknesses in an initiative being led by the UN since 2011 to prevent 
mother-to-child transmission of HIV. Current monitoring methods such as 
electronic pill box monitoring, pill counting, and self-reporting are indirect 
techniques that are highly prone to over-estimation of actual adherence levels7. 
With more accurate data, from direct biochemical measurements, clinicians can 
intervene early and improve adherence to PrEP and HAART regimens before the 
negative consequences of non-adherence manifest. An objective, direct method 
to monitor the drug taken by a patient, such as a point-of-care urine dipstick test, 
would be much more reliable than the currently used indirect methods. 
Current methods for direct measurement of HAART and PrEP drugs involve 
large, expensive, and difficult to use equipment such as high pressure liquid 
chromatography (HPLC) which do not lend themselves well to point-of-care 
solutions for monitoring adherence8. Also, direct detection using HPLC has 
generally required the use of patient plasma. The collection of plasma is more 
invasive and less amenable to point-of-care applications than collecting patient 
urine. The colorimetric solutions investigated in this thesis could provide cheap and 
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flexible alternatives for middle- and low-resource settings to the current direct 
measuring techniques employed in higher-resource laboratories. 
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1.4 Azidothymidine 
Azidothymidine (AZT), marketed initially as Zidovudine, was one of the first 
antiretroviral medications used to combat HIV9, and it is still widely used in low- 
and middle-income countries. In low- and middle-income countries use of AZT by 
clinicians has been rising annually and as of 2011 more than 40% of HAART 
treatments in these areas include AZT3.  A WHO report in 2013 recommends that 
AZT be used in first-line regimens for prophylaxis in infants and children while also 
being an alternative first-line drug for treating adults, including pregnant mothers10. 
AZT works by inhibiting the HIV reverse transcriptase enzyme, which stops the 
production of double-stranded DNA that can be inserted into the host’s DNA11. AZT 
is also prescribed for HIV prophylaxis and as a post-exposure treatment for 
pregnant women to reduce the mother-to-child transmission of the disease12,13. 
AZT (Figure 1) is an analogue of thymidine and thus a nucleotide analogue 
reverse transcriptase inhibitor (NRTI). NRTI drugs most commonly treat HIV as 
AZT does by competitively inhibiting the binding of reverse transcriptase to its 
proper substrate and prevent HIV from correctly synthesizing viral DNA, an 
important step in the HIV virus reproduction cycle14. 3TC, FTC, and TFV are all 
examples of NRTI drugs that are frequently used in HAART and PrEP regimens. 
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Figure 1. NRTI anti-retroviral Drugs for HIV Treatment. A) Azidothymidine, AZT. 
B) Lamivudine, 3TC. C) Emtricitabine, FTC. D) Tenofovir, TFV. 
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1.5 Azide-Alkyne Huisgen Cycloaddition (Click Chemistry) 
The utility of the reaction of terminal azide groups with an alkyne moiety as 
shown in Figure 2 has been known for decades since Rolf Huisgen studied the use 
of this reaction for organic chemistry in 196115. However, the high temperatures 
and times required for the reaction to proceed to completion left much to be 
desired. It wasn’t until a proper catalyst allowing the reaction to proceed at room 
temperature quickly was discovered that the reaction became popular for organic 
chemists and biologists alike. 
Click chemistry was first characterized by Sharpless in 200216. The click 
reaction covalently links an azide side group of one molecule to an alkyne side 
group of another molecule by the formation of a triazole ring. Copper(I) is used to 
catalyze this reaction at room temperature by the reduction of copper(II) sulfate by 
sodium ascorbate. It is the coordination of this catalyst to the resin and its 
dislodgement by AZT that is responsible for the colorimetric output. Click chemistry 
has been used in many applications including drug discovery17, drug delivery18–20, 
polymer synthesis21,22, bioconjugation23–25, nanotechnology26, and material 
science27. A direct measurement of AZT in patient urine would be a marked 
improvement to current adherence measurements. It is well known that the azide 
group in AZT is bio-orthogonal, which means that the reaction of this side group 
with an alkyne side group will not be interfered with by native biochemical 
processes. Also, the azide of AZT is not the primary target involved during 
catabolic modifications28,29. 
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Figure 2. Azide-Alkyne Huisgen Cycloaddition. This reaction requires 98°C and 
18 hours to complete without catalysis. 1) Terminal Alkyne. 2) Terminal Azide. 3) 
1,2,3-triazole (mix of 1,4-adduct and 1,5-adduct).  
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1.6 Lamivudine and Emtricitabine 
Lamivudine is a component of first-line HAART regimens both in high-
income and resource-limited settings. It has a limited toxicity profile and is available 
in fixed-dose regimens30. 3TC works similarly to AZT by inhibiting the HIV reverse 
transcriptase enzyme to stop incorporation of viral DNA into the host’s cells. 3TC 
and AZT are often co-administered and the two drugs have a synergistic effect in 
inhibiting HIV reverse transcriptase activity31. Emtricitabine is nearly identical to 
3TC except for the fluorine atom attached to the 5-carbon of the cytosine base. 
With a method of action identical to that of lamivudine, emtricitabine is a part of the 
standard PrEP regimen along with TFV and is on the WHO’s list of essential 
medicines, which lists the important medications needed for a basic health 
system32. 
The efficacy of FTC versus 3TC has been compared when used with TFV 
and other first-line medications for HAART and PrEP and the two drugs are 
generally accepted as equivalent33. An important distinction, however, is that 3TC 
generics are available that provide more monetary savings for resource-limited 
settings. That being said, both drugs are important for first-line HIV treatments and 
thus proper adherence monitoring of these drugs is vital. 
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1.7 The Wheeler and Johnson Test 
In 1907 Henry Wheeler and Treat Johnson published a study on a color test 
for uracil and cytosine34. The purpose of the study was to develop a chemistry for 
the identification of these nucleosides in solution in an era before the advanced 
characterization techniques we have available today such as HPLC and NMR. In 
this test bromine water is reacted with cytosine or uracil to generate 
dibromohydrouracil. This then decomposes in dilute alkali to isodialuric acid that in 
turn rearranges to dialuric acid both of which give a purple precipitate in the 
presence of barium hydroxide. This test is very sensitive to cytosine and uracil, but 
gives a negative result for thymine and pyrimidine nucleosides35. The mechanism 
of the Wheeler and Johnson test is outlined in Figure 3. 
Since 3TC and FTC are both cytidine analogues we investigated the 
possibility of using the Wheeler and Johnson test to colorimetrically identify these 
molecules in patient urine samples. Not only has this test never been applied to 
ARV drugs but neither has the test been attempted in a solution of urine. However 
there are reasons to expect that the test can be successfully done in urine. The 
most likely source of false-positive signals will be cytosine and uracil possibly 
present in the urine. The concentrations of these nucleosides are extremely low in 
urine, however, and even in renal-compromised individuals the amounts of these 
nucleosides would be insignificant36. A chemistry-based colorimetric assay for 3TC 
and FTC would be a strong alternative to HPLC due to the significantly lower cost 
and minimal expertise required to perform the test. 
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Figure 3. Wheeler and Johnson test mechanism. The conversion of uracil and 
cytosine to isodialuric acid results in visible purple precipitation.  
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1.8 Tenofovir 
Tenofovir (TFV) is a nucleoside reverse transcriptase inhibitor (NRTI) used 
in PrEP and HAART therapies to prevent and manage HIV infections. TFV, like 
NRTIs in general, works by competitively inhibiting the binding of reverse 
transcriptase to its proper substrate and prevents HIV from correctly synthesizing 
viral DNA and replicating properly37. TFV was discovered in 198438 but the 
molecule is not well absorbed upon oral administration so initial applications of the 
drug were limited. However a modified version of the molecule, tenofovir disoproxil 
fumarate (TDF), was developed to enhance the absorption of the drug by oral 
administration39. Once absorbed the TDF pro-drug is metabolized into the anti-HIV 
active TFV molecule, which is the form of the drug as it is cleared from the body. 
TDF is now used in the treatment of both HIV and hepatitis B and is on the WHO’s 
list of essential medicines40. TDF is an integral part of the WHO’s recommended 
first-line drug regimen for the treatment of HIV-infected individuals in low- and 
middle-income countries32. 
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1.9 Antibodies and Lateral Flow Strips 
 Antibodies are an invaluable tool for biological investigation and 
engineering. The high sensitivity and specificity of antibodies is utilized in many 
important validation and processing methods such as immunoblotting, ELISAs, 
chromatographic separations, immunoprecipitation, and immunosensors41. 
Antibodies that are sensitive to specific analytes are raised by injecting target 
molecules into a host animal to induce an immunogenic response that generates 
antibodies against the foreign molecules in the host’s serum. While most 
antibodies used in clinical, industrial, or personal settings target large molecules 
such as peptides and proteins there are many antibodies that have been used to 
target small molecules42–46. Antibody-based sensors, such as pregnancy tests, are 
ubiquitous for instrument-free and colorimetric-based lateral flow assays47.  
Lateral flow strips are used in a wide array of applications including home 
pregnancy tests48 and point-of-care immunodiagnostics49–51. However, lateral flow 
assays have yet to be widely deployed in monitoring adherence habits of HIV 
patients taking PrEP or other HAART medications. Such a platform offers many 
benefits including point-of-care applications, shorter run times, and clear results 
for both clinician and patient52. A urine-based, point-of-care lateral flow device 
would be a useful tool for clinicians to monitor adherence habits and improve 
patient care through timely intervention upon the discovery of non-adherence. 
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Chapter 2: Colorimetric Detection of Azidothymidine Using an Alkyne-
Modified Dextran Substrate  
 
This chapter focuses on Aim 1 of my thesis work. The goal of this work was 
to develop a point-of-care method for the detection of AZT in the urine of patients 
taking the ARV using a simple dipstick-based test. By eliminating the need for 
expensive equipment or even the need for being in a standard clinical setting this 
work provides another tool for clinicians to monitor the adherence habits of their 
HIV patients and alert them for intervention in cases of non-adherence. 
  
17 
 
2.1 Significance 
In Chapter 1 I have discussed how click chemistry can be used to react with 
a target molecule containing an azide, such as AZT, even in a complex solution 
such as urine. This chapter will be focused on Aim 1: Develop a dipstick based 
point-of-care device for the detection of AZT in urine. 
Our initial work on direct measurements of AZT using click chemistry 
demonstrates the viability of a paper-based substrate to perform a urine test53. 
Based on a thin-liquid chromatography stain to detect organic azides first 
developed by Bräse et al.54, we developed an assay to test urine samples for the 
presence of AZT. This assay allowed for colorimetric detection of the drug without 
the need for expensive equipment. 
However, this initial work did not achieve sensitivities that are 
physiologically relevant without sample concentration and required specific 
staining reagents that added complexity and handling concerns to the test. 
Therefore, we further developed an assay that does not require stains, gives a 
clearer colorimetric readout, and is sensitive enough to be physiologically relevant 
to monitoring patient drug adherence. 
The assay described here is a point-of-care dipstick-based direct measure 
of AZT in urine, as outlined in Figure 4, by targeting the azide group of AZT in an 
azide-alkyne cycloaddition “click chemistry” reaction with a modified dextran 
molecule containing terminal alkyne side groups. This click chemistry was first 
characterized by Sharpless in 200216. The click reaction covalently links an azide 
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side group of one molecule to an alkyne side group of another molecule by the 
formation of a triazole ring. Copper(I) is used to catalyze this reaction at room 
temperature by the reduction of copper(II) in situ. It is the coordination of this 
catalyst to the alkyne substrate and its dislodgement by AZT that is responsible for 
the color change. The application to detect azide containing drugs was suggested 
by Bertozzi in 200455.  Human urine does not naturally contain azide-containing 
molecules and native biochemical processes will not interfere with the reaction of 
the AZT azide with an alkyne side group. 
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Figure 4. Schematic of assay to detect AZT in patient urine. 
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2.2 Methods 
Alkyne-dextran Synthesis  
Functionalization of dextran (MW 10,000 or MW 2,000,000) was performed 
by a protocol outlined by Heller et al56. Briefly, 0.78 g of 1,1’ carbonyldiimidazole 
(CDI) (2.4085 mmole) was dissolved in 10 mL of dry DMSO under nitrogen. 900 µl 
of 4-pentyn-1-ol (4.82 mmole) was then added drop-wise. After mixing for 2 hours 
under nitrogen, the solution was added to 500 mg of dry dextran and 80 mg of dry 
4-(dimethylamino) pyridine (DMAP), then stirred for another 48 hours. The polymer 
was purified by dialysis for at least 48 hours against deionized water with the water 
changed twice daily. The solution was then frozen and lyophilized for at least 48 
hours until dry. 
 
Azidothymidine Staining Assay 
 50µL propargyl alcohol was mixed with a solution of copper(I) bromide in 
dimethyl sulfoxide (DMSO) and ethanol (20 mg Cu(I)Br in 7.25 mL DMSO/0.75 mL 
ethanol). The resulting “Click Solution” mixture was added to Gel Blotting Paper. 
A 2.5 µL drop of urine or water samples was added to the Gel Blotting Paper and 
heated in an oven at 60°C for 30 minutes. A staining solution of either Seebach 
staining solution (2.5 g phosphomolybdic acid, 1 g cerium(IV) sulfate, 6 mL 
concentrated sulfuric acid, 94 mL water) or ammonium persulfate solution (260 
mM) was added drop-wise to the sample spots and returned to the oven at 60°C 
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for 5 minutes. Results were recorded by a Nikon D3100 camera and processed by 
Adobe Photoshop CS6. 
 
NMR Characterization  
NMR was recorded on a Varian instrument. AZT-Propargyl Alcohol 1.75 (s, 
3H, CH3), 2.61–2.63 (dd, 2H, CH2), 3.18 (s, 1H, CH), 3.58–3.61 (dd, 2H, CH2), 
3.67 (s, 1H, CH), 4.00 (s, 2H, CH2), 4.52 (m, 1H, CH), 5.25 (m, 1H, OH), 5.34 (m, 
1H, OH), 6.39 (t, 1H, CH), 7.79 (s, 1H, CH), 8.20 (s, 1H, CH), 11.30 (s, 1H, NH); 
Ethanol 0.98 (s, 2H, CH2), 3.36 (s, 3H, CH3), 4.27 (s, 1H, OH). 
AZT-Alkyne-Dextran (MW 10,000) 1H NMR (500 MHz, D2O, δ): 4.8 (s, 2H, 
OH), 5.0 (s, 1H, CH), 3.9–4.1 (m, 1H, CH), 3.6–3.7 (m, 1H, OH), 3.8 (s, 2H, 
CH2¬¬), 1.9 (s, 2H, CH2), 2.3 (s, 1H, CH), 4.3 (s, 2H, CH2), 2.1 (s, 3H, CH3), 2.8–
3.0 (d, 2H, CH2), 4.5 (s, 1H, CH), 5.4–5.5 (d, 1H, OH), 6.5 (s, 1H, CH), 7.8 (s, 1H, 
CH), 8.1 (s, 1H, CH). 
Alkyne-dextran (MW 2,000,000) 1H NMR (500 MHz, D2O, δ): 4.8 (s, 2H, 
OH), 5.0 (s, 1H, CH), 3.8–4.0 (m, 1H, CH), 3.5–3.6 (m, 1H, OH), 3.7 (s, 2H, 
CH2¬¬), 1.9 (s, 2H, CH2), 2.4 (s, 1H, CH), 4.3 (s, 2H, CH2), 5.3–5.4 (d, 1H, OH). 
 
UV-Vis Spectroscopy 
UV-Vis spectra of the AZT staining assay were recorded on a Thermo Scientific 
Nanodrop 2000C Spectrophotometer. 
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Azidothymidine Dextran Assay  
For the in-tube assay 5mg MW 2,000,000 40% functionalized alkyne-
dextran was incubated with 3mg copper(II) sulfate and 7mg sodium ascorbate in 
1mL Tris buffer (pH 8) for at least 30 minutes in a 55°C water bath. The solution 
was spun down for 1 minute at 12,000g and the supernatant removed. The pellet 
was washed twice with Tris buffer and left in darkness overnight. The resulting 
“pre-treated” green pellet was then incubated with 1ml of the sample to be assayed 
(either in Tris buffer or urine) in the presence of copper(II) sulfate and sodium 
ascorbate for at least 30 minutes in a 55°C water bath. The solution was spun 
down for 1 minute at 12,000g and the supernatant removed. The pellet was 
washed twice in Tris buffer before visual inspection of the pellet. 
For the dipstick test 5mg MW 2,000,000 40% functionalized alkyne-dextran 
was ground up into a powder. Rubber cement was then applied to a 4mm x 4mm 
black paper square which was pressed onto the crushed powder. This square was 
then glued onto a 40mm x 4mm black paper strip to create a dipstick. The dipstick 
was then incubated in 50mL Tris buffer (pH 8) containing 29mM sodium ascorbate 
and 7.7mM copper(II) sulfate for at least 30 minutes in a 55°C water bath. The 
dipstick was then washed briefly in Tris buffer and left in darkness overnight. The 
pre-treated dipstick was then incubated in 50mL urine solution containing 100mM 
Tris buffer, 29mM sodium ascorbate, and 7.7mM copper(II) sulfate for at least 75 
minutes in a 80°C water bath. The dipstick was then washed briefly in Tris buffer 
before visual inspection of the dipstick. 
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Disproportionation Reaction  
Alkyne-dextran that has been reacted with AZT was washed in Tris pH 8.0 
buffer with the supernatant removed. The same was done with a no AZT control. 
The pellets were placed in 50mM sulfuric acid solution, heated to 80°C, and 
incubated overnight. 
 
Image Analysis  
Pictures of dipsticks were taken with a Nikon D3100 camera and analyzed 
by ImageJ. RGB analysis was done on the colorimetric output using the ImageJ 
“Measure RGB” plug-in to determine a quantitative value for negative (yellow) and 
positive (white) results. 
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2.3 AZT Staining Results and Discussion 
The assay results in Figure 5a show how AZT is detectable in both urine 
and water by the generation of orange-colored spots. In addition, the lack of color 
generation in the 3’-deoxythymidine (DDT) (azideindependent analogue of AZT), 
thymidine (natural pyrimidine deoxynucleoside analogue), and cytosine (pure 
pyrimidine) negative controls suggests that the presence of orange spots is azide-
dependent. The detection limit of AZT in solution was found to be around 12 mM. 
The exclusion of propargyl alcohol or copper(I) bromide from the “Click 
Solution” in Figure 5b and 5c, respectively, resulted in no visible orange spots, 
which further suggests that the assay is propargyl alcohol and Cu(I)-dependent. 
Therefore, we hypothesize that a bona fide click reaction between the azide group 
of AZT and the alkyne group of propargyl alcohol catalyzed by the Cu(I) in the 
“Click Solution” is occurring in the paper matrix during the assay. To support this 
hypothesis, NMR was performed on AZT samples mixed with propargyl alcohol 
and copper(I) bromide in a DMSO-d6/ethanol-d6 solution. The peak located at 8.20 
ppm corresponds to the proton in the triazole ring that develops during the click 
reaction57. 
 While the NMR spectra in Figure 6 confirm that a click reaction does take 
place in conditions present in the assay, the sodium azide control samples in 
Figure 5 are colorimetrically invisible on the paper matrix. We then ask whether or 
not the resulting compounds in the sodium azide sample either absorbed light 
outside of the visible spectrum or the color generation was too weak for normal 
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digital photography. The assay was repeated in PCR tubes, incubated in a 
thermocycler at 60°C, and the resulting UV-Vis spectra in Figure 7 confirms that 
only the AZT samples absorbed significant light in the visual range. This suggests 
that, while a click reaction is occurring in sodium azide samples, the resulting 
compounds are not conducive to a visual assay. 
 Since the sodium azide sample cannot be visually detected by the assay 
and other azide-containing compounds tested in Figure 8 give varying results the 
specificity of the assay to AZT cannot be wholly attributed to click chemistry. More 
work needs to be done to elucidate the mechanism of both the orange-color 
generation in the AZT-specific spots on paper, and conversely, the lack of color 
generation in other azide moieties in the presence of our “Click Solution”. 
 The 12 mM detection limit of our assay is not low enough to be 
physiologically relevant. AZT in the HAART regimen is the active ingredient of 
Zidovudine. One tablet of Zidovudine contains 300 mg of the active ingredient and 
the indicated dosage is 600 mg/24 hours. The urine output of a patient varies, but 
on average, 150–250 ml of urine output per urination is a reasonable volume. This 
gives a maximum of 2.4 mg/ml (9mM) of detectable AZT in the urine (if the entire 
drug is excreted in one sample of urine).  
To implement this assay effectively, a clinician collects a urine sample from 
the patient, concentrates it by evaporation on a hot plate, and assays the sample 
on paper to be compared against a strip with standards to determine how much 
AZT is present. This scheme is outlined in Figure 9. Further tests need to be done 
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to ensure that the concentration of urine samples would not negatively affect the 
colorimetric response of AZT samples. 
 This work is a proof-of-concept of a fast and reliable assay to detect the 
presence of AZT in patient urine. Future work will include further elucidation of the 
mechanism of action, increasing the sensitivity of the assay, and developing a 
marketable point-of-care device that can be used by clinicians. A reliable test to 
monitor patients on HAART regimens will increase the accuracy of information 
received by the clinic and drive down the costs associated with patient non-
compliance. 
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Figure 5.  AZT Assay on cellulose paper. Each row is comprised of six sample 
spots of descending concentration: 50mM, 37.5mM, 26.25mM, 18.75mM, 
11.25mM, 3.75mM. The Control Row consists of the following samples: 
thymidine in water (50mM), thymidine in urine (50mM), cytosine in water (50mM), 
cytosine in urine (50mM), water, positive urine (contains amino acids), negative 
urine (contains no amino acids). a) Click Solution with propargyl alcohol and 
CuBr. b) Click Solution with no propargyl alcohol. c) Click Solution with no CuBr.  
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Figure 6. 1H NMR spectra of AZT and propargyl alcohol in the presence of 
copper(I) in DMSO-d6/ethanol-d6 solution. 
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Figure 7. UV-Vis of AZT Assay. Absorbance of compounds assayed across the 
visible spectrum. 
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Figure 8. AZT assay tested against various azide containing compounds. 
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Figure 9. Schematic of AZT assay implementation. 
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2.4 AZT Dextran Assay Results 
Dextran Functionalization with Alkyne side-groups 
To successfully detect AZT, dextran must first be functionalized to contain 
a terminal alkyne side group so that it can participate in the click reaction with the 
azide side group of AZT. The alkyne-containing ligand, 4-pentyn-1-ol, reacts with 
the hydroxyl side group on the 3rd carbon of the glucose monomer in dextran after 
activation by CDI56. Figure 10 (inserts i and ii) shows the NMR spectra of native 
dextran and the product of this reaction, respectively. The additional peaks at 1.94, 
2.37, and 4.35 ppm correlate to the alkyne ligand that has been added through the 
conjugation reaction. By integrating these peaks, normalizing for the number of 
protons and comparing them to a native dextran peak, we are able to determine 
that about 10% of the dextran has been substituted with the alkyne ligand. By 
increasing the proportion of 4-pentyn-1-ol we were able to increase the substitution 
percentage to as high as 40%. We then reacted the alkyne-dextran with AZT in a 
click reaction. Figure 10 shows that after purification, the product has several 
additional peaks, including the peak at 8.01 ppm that correlates to the proton in 
the triazole ring that can only form during the click reaction between AZT and the 
alkyne-dextran57. For the assay we prefer to use an alkyne-dextran that is relatively 
insoluble in water in order to start and finish the assay with a solid pellet for easy 
visual inspection. 2,000,000 MW dextran with a 40% functionalization of the alkyne 
side-group was investigated for the visual assay.  
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Figure 10. 1H NMR spectra of alkyne-dextran (10,000MW dextran, 10% 
functionalization) after click reaction with AZT in D2O. Insert i) 1H NMR spectra of 
dextran in D2O ii) 1H NMR spectra of alkyne-dextran in D2O. 
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Colorimetric Azidothymidine Assay 
While NMR spectra clearly indicate the presence of AZT on the alkyne-
dextran, NMR would have little use in a resource-limited setting. However, a 
colorimetric signal caused by the click reaction allows us to determine the 
presence of AZT in the sample based on visual inspection. However, the color 
change is different when click chemistry is performed in the presence and absence 
of the azide-containing AZT molecule (Figure 11). Alkyne-dextran samples that 
were pre-treated with copper(II) sulfate and sodium ascorbate have a clear green 
color after washing and overnight storage in darkness. When click chemistry is 
performed on this green alkyne-dextran in the presence of AZT, the pellet turns 
white. When it is performed in the absence of AZT the pellet turns yellow. 
Larger scale incubations have shown that the in-tube assay can positively 
detect AZT at a concentration as low as 500µM in urine. Additionally, the assay 
was performed in the presence of other HAART medications: abcavir, and 
lamivudine. Only the AZT has an azide group and only samples containing AZT 
gave a positive result as shown in Figure 12 and Figure 13. This demonstrates that 
the test is specific enough to only detect molecules containing a terminal azide, a 
side group that is not normally present in human urine. 
The assay was tested in a dipstick format to determine its viability as a point-
of-care device. Image analysis allows for the quantitative evaluation of the 
colorimetric output. RGB values were determined and the blue channel value was 
normalized to the mean value of the red and green channels. Thus, a normalized 
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value close to zero means the image is dominated by red and green light which 
gives a yellow appearance. Conversely a value close to one means the image is 
equally comprised of red, green, and blue light which gives a white appearance. 
The limit of detection results in Figure 14 show sensitivities of the point-of-care 
device as low as 750µM AZT in urine along with representative photos for positive 
and negative results. The data suggests a threshold between 150µM and 750µM 
AZT below which the assay gives a negative (yellow) output and above which the 
assay gives a positive (white) output. 
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Figure 11. A) Alkyne-dextran Assay to test for AZT. o) Pre-treated 2,000,000 MW 
40% functionalized alkyne-dextran used in the assay. B) Positive detection of 
500uM AZT in urine. 
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Figure 12. A) Selectivity Experiments with different HAART medications 
performed in Tris. B) RGB Histogram (blue channel). 
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Figure 13. Blue channel mode normalized to mean of RG channel modes. Values 
closer to 0 are more yellow while values closer to 1 are more white. 
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Figure 14. A) Representative negative dipstick result (0–150µM AZT). B) 
Representative positive dipstick result (750µM AZT or higher). C) Quantitative limit 
of detection data (n=3) measuring colorimetric output for dipstick assay. 
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2.5 AZT Dextran Assay Discussion 
Fresh alkyne-dextran is white, but when it is incubated in a solution of 
copper(II) sulfate and sodium ascorbate in Tris buffer, it turns yellow. We 
hypothesize that this yellow color comes from the copper(I) species, generated by 
the sodium ascorbate, coordinating with the alkyne side group in the first step of 
the click reaction to form a copper acetylide58. While it is known that the formation 
of a copper acetylide species is the first step in the click reaction, and that copper(I) 
appears yellow, we wanted to show this was the source of the yellow color on the 
alkyne-dextran. To do this, we incubated the yellow product in a solution of dilute 
sulfuric acid and heated the sample. The sample turned brown, which was the 
expected result, since copper(I) will react with sulfuric acid upon heating in a 
disproportionation reaction to generate copper(II) and copper(0), which will remain 
insoluble and appear brown (Figure 15)59. 
After the formation of copper acetylide, the next step of the click reaction 
involves the azide containing molecule forming a triazole ring with the alkyne 
containing molecule and dislodging the coordinated copper(I) species. We 
hypothesize that the loss of copper(I) due to the completion of the click reaction is 
what causes the alkyne-dextran substrate to turn white in the presence of an azide-
containing molecule. There is a drawback to this reaction scheme, however. The 
positive AZT sample appears white, which is the same color as the unreacted 
alkyne-dextran. This ambiguity is a potential source of confusion for the operator. 
To avoid this problem, we pre-treated our alkyne-dextran samples with copper by 
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reacting it with copper(II) sulfate and sodium ascorbate to generate yellow alkyne-
dextran. Interestingly, when we wash these pre-treated samples with Tris and 
incubate them at room temperature overnight in a small amount of buffer the 
samples turn green. 
With pre-treated green alkyne-dextran as the starting material, the assay 
gives a clear readout for a positive or negative result.  An additional consideration 
is the potential of dark or yellow urine interfering with the colorimetric output. The 
in-tube and dipstick experiments were all performed in highly colored urine and 
after a brief wash in Tris buffer there were only minor discolorations of the positive 
white output when compared to the Tris samples in Figure 11. This minor 
discoloration can be seen in the representative examples in Figure 14 but the effect 
does not confound the results and the positive output can still be discerned both 
qualitatively and quantitatively. Should more color contrast be necessary, an 
additional incubation step in heated, dilute sulfuric acid will convert the copper(I) 
on the pellet to copper(0) which appears brown. 
The standard dosage of AZT for adults is approximately 600mg per day. 
Given that 14 percent of the drug will be excreted in the urine as AZT and 74% of 
the drug will be excreted in the glucouronide form60, 528 mg of AZT will be present 
in a day’s worth of urine61. According to the NIH, the average volume of urine per 
day is between 800 and 2000mL62. Therefore, the assay must be sensitive enough 
to detect AZT at a concentration of 940µM – 3.1mM. The results shown in Figure 
14 show a positive detection of AZT in urine at a concentration of 750µM. Although 
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not yet tested with this assay, the glucuronide form of the molecule also contains 
a free azide group, which can be detected by the assay. 
Direct measurements of AZT have been done using HPLC to measure 
plasma samples8. While this is the current standard for measuring AZT it is not a 
practical solution for monitoring patient adherence habits in resource limited 
settings. HPLC is an expensive technique that requires trained technicians to use 
and must be performed in a laboratory setting and requires plasma samples. The 
alkyne-dextran dipstick, however, is simple to use and can be deployed both in 
clinics and outside laboratory environments at the point-of-care while only requiring 
around 50mL of patient urine. With the limit of detection for the dipstick assay 
around 750µM of AZT in urine the alkyne-dextran dipstick is both sensitive and 
specific enough to be used as a point-of-care device in resource limited settings. 
The dipsticks are simple to make and require minimal urine sample preparation. 
This preparation involves the addition of sodium ascorbate, copper(II) sulfate, and 
Tris buffer to the urine sample before beginning the assay. All of these reagents 
can be stored and transported dry before use in the assay. While the sample must 
be heated to 80°C, this can be achieved on a hot plate, water bath, or even a stove 
top. 
The specificity of the current dipstick assay means that it can only be 
applicable in detecting metabolites that contain azide side groups. Of all relevant 
HAART medications only AZT and the AZT-analogue Nikavir contains such a side 
group and thus can be detected by this assay. However, with the significant AZT 
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use in resource limited settings3 and the WHO’s recommendation that it continue 
to be used in certain first-line regimens as well as being one of the first alternatives 
used after treatment failure10 this point-of-care assay can be a useful part of the 
clinician’s toolbox in monitoring patient adherence habits. 
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Figure 15. Disproportionation reaction. Left sample contains 10mg AZT. Right 
sample contains no AZT. 
 
  
45 
 
2.6 Conclusions 
The World Health Organization (WHO) stated in a 2013 report that in 
treating pregnant women with HIV to limit mother-to-child transmission of the 
disease “it is not possible to determine adherence to the regimen in most cases”6. 
The WHO mentions this as a weaknesses in an initiative being led by the UN since 
2011 to prevent mother-to-child transmission of HIV. This highlights the need for a 
point-of-care device that can directly measure adherence. This work has shown 
that alkyne-modified dextran can be used to detect the HAART drug AZT at 
physiologically relevant concentrations in urine in a portable, flexible, and 
minimally invasive point-of-care platform. Since the readout is colorimetric and the 
procedure is simple, no special expertise is required to check patient adherence 
habits. 
In this work, we have utilized a modified dextran molecule to detect the 
presence of a therapeutic azide, AZT, using click chemistry on a dipstick platform. 
Since dextran can also be functionalized with an azide side-group we will explore 
detecting alkyne-containing drugs such as Efavirenz, another HAART drug 
recommended for prophylaxis increasingly being used5, or other azide containing 
drugs such as Nikavir, which is an AZT analogue, to further broaden the scope of 
this novel point-of-care device.  
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Chapter 3: Colorimetric Detection of Lamivudine and Emtricitabine Using a 
Modified Nucleoside Assay 
 
 This chapter focuses on Aim 2 of my thesis work. The goal of this work was 
to develop a detection method of 3TC and FTC in urine using a straightforward 
lab-based test. While the test does require a trained technician to perform it does 
eliminate the need for expensive equipment such as HPLC and gives a very clear 
read-out. Since 3TC and FTC are currently key ARV drugs an assay to detect their 
presence in urine could be an important tool for doctors monitoring their HIV 
patients.  
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3.1 Significance 
 In Chapter 1 I have discussed the Wheeler and Johnson test that was 
originally conceived to detect cytosine and uracil nucleosides in solution. Both 3TC 
and FTC are analogues of cytidine and thus we investigated applying the Wheeler 
and Johnson test to these molecules. This chapter will be focused on Aim 2: 
Develop a colorimetric assay for the detection of 3TC and FTC in urine. 
 Lamivudine was first developed in 1988. In 1991 Yung-Chi Chen discovered 
the powerful synergy between 3TC and AZT. When the two drugs were used in 
combination it was shown that negative side effects were reduced and the overall 
efficacy of the treatment increased63. The combination of AZT and 3TC was 
approved by the FDA to treat HIV in 1995. Today, 3TC is still widely prescribed 
and is the main NRTI used in China64. For adherence monitoring there is no direct 
measure of 3TC levels in patients except by HPLC mass spectrometry 
measurements of patient samples64,65. As stated in chapter 1, HPLC is both an 
expensive and non-trivial way to measure drug levels in patients. 
Emtricitabine was first developed in 1996. The fluorine atom bonded to the 
5-carbon of the cytosine base is the only molecular difference between FTC and 
3TC. The molecules are so similar, in fact, that when drug resistance does develop 
the virus gains nearly complete cross-resistance to both 3TC and FTC even when 
only one of the drugs is present66. While used to treat those infected with HIV, FTC 
is also paired with TDF in PrEP medications. Like 3TC, direct measurements of 
FTC levels in patients is limited to HPLC67,68. 
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Our work will demonstrate the first colorimetric test for the determination of 
3TC and FTC in urine. We have repurposed the Wheeler and Johnson test first 
developed in 1907 to detect these cytidine analogues. Originally the test was used 
to detect cytosine and uracil molecules during the study of DNA and nucleic acids 
before the advent of modern detection techniques. We have leveraged this test to 
now detect 3TC and FTC without HPLC or other expensive equipment. In short, 
the Wheeler and Johnson test converts the cytidine analogues into uridine 
analogues through deamination by heat followed by halogenation of the base and 
nucleophilic substitution with alcohol to generate a colored precipitate that is 
clearly visible for adherence monitoring. 
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3.2 Methods 
3TC and FTC Assay 
To a solution of 3TC or FTC (at least 200µg/mL) bromine water is added 
until the orange/yellow color is persistent. The solution is placed on a hotplate until 
it begins to boil. The solution is boiled for at least 20 minutes then allowed to cool 
to room temperature. Small amounts of bromine water are titrated until the solution 
just starts to turn yellow. 0.1M BaOH is slowly added until purple precipitate forms 
indicating the presence of 3TC or FTC. 
 
3TC Assay in Urine  
To a urine sample spiked with 3TC (at least 2.4mg/mL) barium hydroxide 
and barium chloride is added at a volumetric ratio of 1:0.5:0.4, respectively. The 
solution is spun down and the supernatant is assayed as described above. Briefly, 
bromine water is added until the solution clearly begins to turn orange. The sample 
is boiled for at least 20 minutes and allowed to cool to room temperature. A small 
amount of bromine water is added followed by slow addition of 0.1M barium 
hydroxide until purple precipitate forms. 
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3.3 Results and Discussion 
3TC and FTC are both cytidine analogues and, although cytidine is not 
detected by the Wheeler and Johnson test, we investigated the possibility of using 
the test to colorimetrically identify these molecules both in water and in urine. Not 
only has this test never been applied to ARV drugs but neither has the test been 
attempted in a solution of urine. The most likely source of false-positive signals 
would be cytosine and uracil possibly present in the urine. The concentrations of 
these pyrimidines are extremely low in urine, however, and even in renal-
compromised individuals the amounts of these free pyrimidines would be 
insignificant36. A chemistry-based colorimetric assay for 3TC and FTC would be a 
strong alternative to HPLC due to the significantly lower cost and minimal expertise 
required to perform the test. 
The 3TC/FTC assay results in Figure 16a show a strong colorimetric signal 
upon the addition of barium hydroxide to the solution. This purple precipitate is 
very similar in color when the assay is applied to uracil and cytosine, the positive 
controls, as originally done by Wheeler and Johnson. This demonstrates the 
feasibility of adapting the Wheeler and Johnson test for detecting pyrimidine 
analogues such as 3TC and FTC. 
The assay gives a negative result when applied to cytidine, the negative 
control, as shown in Figure 16b. The Wheeler and Johnson test is known to be 
insensitive to purines and pyrimidine nucleosides35 such as cytidine. We cannot 
yet say why 3TC and FTC are detected by the Wheeler and Johnson test when 
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cytidine is not. The assay was repeated with varying amounts of 3TC to determine 
the limit of detection. It was found that below 200µg/mL (840µM) 3TC was 
undetectable in water (Figure 16c). 
We next applied the assay to spiked urine samples to determine if urine 
could be directly tested for the presence of 3TC. When the assay is performed 
directly in urine the addition of barium hydroxide results in a large amount of 
precipitation regardless of the presence of 3TC. It has been noted previously that 
barium ions will pair with sulfate and phosphate ions present in urine and 
precipitate from solution69. In order to avoid interference from these ions we pre-
treated our spiked urine samples with barium hydroxide and barium chloride to 
precipitate out the sulfate and phosphate ions before the 3TC/FTC assay was 
performed on the supernatant. Figure 17 shows that after pre-treatment the 
3TC/FTC assay can colorimetrically detect the drug in urine while having no effect 
on a negative control containing cytidine. The sensitivity of the assay in urine was 
found to be around 2mM. We speculate that the additional volume added to the 
sample during pre-treatment increases the minimum concentration of drug 
required to generate visible signal. 
The assay in its current format shows clear signal of 3TC and FTC in water 
and 3TC in urine (FTC has not yet been tested in urine). These results can be 
obtained without expensive equipment like HPLC and NMR in less than an hour. 
However, with sensitivities of 870µM in water and 2mM in urine, the assay needs 
to be improved before it can be deployed in clinics. The standard dosage of 3TC 
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is 300mg a day for treating HIV with about 70% renal clearance70. With a 800–
2000mL volume range of urine per day71 for the average person a reasonable 
concentration window of 3TC in urine is 460–1150µM. For the assay to be reliable 
in the clinic the sensitivity needs to be improved at least 6-fold in urine. Also, the 
amount of bromine water and barium hydroxide required for the assay can vary 
depending on both the hydration level of the urine and the concentration of ARV 
drug present in the sample. With a more detailed knowledge of reagent 
requirements relative to these variables a more semi-quantitative assay could be 
developed. 
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Figure 16. A) 3TC/FTC assay in water. B) Selectivity test of 3TC/FTC assay in 
water. C) Sensitivity test of 3TC/FTC assay in water. 
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Figure 17. 3TC Assay in spiked urine sample (2.4mg/mL 3TC starting 
concentration). 
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3.4 Conclusions 
We have demonstrated the first successful application of the Wheeler and 
Johnson test to detect ARV drugs in urine. Although the sensitivity needs to be 
improved before the assay can be deployed in the clinic, this is a promising first 
step in developing a method for the direct detection of ARV drugs in patient urine 
to objectively monitor adherence patterns. Future work should investigate the 
concentration of urine samples to increase the effective starting concentration of 
ARV drugs for the assay. A more precise protocol covering a range of urine 
hydrations should be defined to optimize the sensitivity of the assay and minimize 
reagents. Finally, it should be explored how best to deploy this assay as a point-
of-care device in the field due to the volatility and toxicity of the reagents required 
to run the assay. 
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Chapter 4: Characterization of a Tenofovir-Sensitive Aptamer in a Lateral 
Flow Setting 
 
 This chapter focuses on my characterizations of a commercially available 
TFV-sensitive aptamer for lateral flow applications. Since Aim 3 of my thesis is to 
develop a lateral flow test for TFV we first investigated if this commercially 
available TFV aptamer would be appropriate to use rather than raising our own 
TFV-sensitive binding substrate. While data from the manufacturer shows that the 
aptamer performs well in solution we wanted to demonstrate its feasibility for use 
by testing the aptamer in lateral flow set ups. 
 
  
57 
 
4.1 Significance 
 Aptamers are oligonucleotides or peptides that are specifically designed to 
bind to a target molecule. For oligonucleotide based aptamers the nucleic acids of 
the molecule directly interact with the target molecule to bind it to the aptamer 
through forces such as hydrogen-bonding, electrostatic interactions, and van der 
Waals forces. Additionally, nucleic acid aptamers will form secondary structures 
through the complimentary base pair interactions within the oligonucleotide. The 
combination of these intermolecular and intramolecular interactions results in the 
unique binding properties of the aptamer. 
 Aptamers were initially developed in 1990 independently by the labs of Larry 
Gold and Jack Szostak. Since then the methods of developing aptamers have 
improved such that in 2004 Macugen, developed to treat macular degeneration, 
became the first aptamer-based therapeutic to be approved by the FDA. Beyond 
just therapeutics, aptamers are also used for biosensing72–74 applications and as 
substitutes for antibodies as affinity reagents. 
 As a substitute for antibodies, aptamers have several desirable advantages. 
Aptamers can be reliably synthesized chemically rather than relying on a host 
organism to generate the molecules resulting in less batch-to-batch variability and 
reduced long term costs. When used therapeutically, aptamers are non-
immunogenic and their smaller size relative to antibodies gives them access to 
more tissues. Additionally, aptamers can be reversibly denatured and are more 
stable at room temperature giving them superior shelf-life over antibodies. 
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Aptamers are no silver bullet, however. Aptamers are more prone to enzymatic 
degradation and have a shorter half-life in the body. 
 The most common way to raise aptamers is by systemic evolution of ligands 
by exponential enrichment (SELEX) (Figure 18). In short, a large starting library of 
aptamer candidates are screened against immobilized target. The aptamers that 
bind the target are isolated from the library and are amplified through PCR to create 
a larger population of binders. This new population is then screened again against 
the immobilized target. The stringency of these screenings is increased as the 
rounds progress until after many rounds only the strongest binders make up the 
amplified population. These best candidates are then sequenced so that the 
aptamer can be chemically synthesized in the future. 
 In part due to their small size, aptamers can be deployed to detect small 
molecule targets in lateral flow set ups. For example, a modified ATP aptamer was 
used to develop a colorimetric lateral flow assay75. With this in mind, we explored 
using a commercially available TFV aptamer from Base Pair Biotechnologies to be 
our binding molecule for a colorimetric TFV lateral flow assay. The TFV aptamer 
has been shown to successfully bind TFV with a Kd between 1 and 10nM76,77 
(Figure 19) and we hoped it would be capable of binding when it is immobilized on 
a surface as it would in a lateral flow test. 
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Figure 18. Schematic of the SELEX process to raise aptamers. 
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Figure 19. A) Back-Scattering Interferometry (BSI) characterization of TFV 
aptamer binding76. B) Microscale Thermophoresis (MST) characterization of TFV 
aptamer binding77. 
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4.2 Methods 
Aptamer binding on lateral flow strip 
 Biotinylated TFV-aptamer was purchased from Base Pair Biotechnologies. 
A bare strip of nitrocellulose was spotted multiple times with 1uL spots of 
1mg/mL streptavidin. The strips were allowed to dry for at least 10 minutes 
followed by visualization by Ponceau stain. The strips were then incubated in 5% 
BSA solution in TBS-T for at least 30 minutes. The strips were washed three 
times with TBS-T buffer followed by active washing of the strips with either a 1:50 
dilution of 10µM biotinylated TFV-aptamer in PBS with 1mM MgCl2 (TFV+), 1:50 
dilution of 10µM biotinylated nonsense sequence (nonsense), or TBS-T (NULL) 
for 10 minutes. The strips were again washed three times with TBS-T. The strips 
were then incubated by active washing of 1:50 dilution of 1mg/mL TFV in PBS 
with 1mM MgCl2 for 10 minutes. The strips were then washed either zero, one, 
two, three, or four times with TBS-T. The strips were then boiled for 10 minutes in 
a solution of 975µL 0.6% trifluoroacetic acid in water and 25µL methanol. The 
sample was then analyzed by LC-MS. LC-MS measurements were taken on an 
Agilent 1100 series LC/MSD with a Cortecs C18 column (90Å, 2.7 µm, 4.6 mm X 
150 mm) from Waters. 20µL of sample was injected into a gradient mobile phase 
outlined in Table 1 at a flowrate of 0.6mL/min into the column equilibrated at 
45°C and passed through the mass spectrometer set for positive polarity 
electrospray ionization (ESI+) at a range of 100–1500 m/z. 
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Aptamer Characterization by Surface Plasmon Resonance (SPR) 
 SPR measurements were taken on a Biacore T-100 on a Series S Sensor 
Chip SA. 3’-biotin-spacer-TFV aptamer and 5’-biotin-spacer-TFV aptamer were 
purchased. The biotinylated aptamers were diluted down to 100nM in Running 
Buffer (PBS with 1mM MgCl2 and 0.05% Tween-20). Three 1 minute pulses of 
1M NaCl and 50mM NaOH were done at a flowrate of 10µL/min in all flow cells. 
3’-biotin aptamer was run in flow cell 2 (flow cell 1 was used as a control) for 12 
minutes. 5’-biotin aptamer was run in flow cell 4 (flow cell 3 was used as a 
control) for 12 minutes. 100ng/mL of TFV in Running Buffer was run over all cells 
for 5 minutes followed by 5 minutes of Running Buffer alone. 1µg/mL of TFV was 
then run over all cells for 5 minutes followed by 5 minutes of Running Buffer 
alone. This process was repeated for 10µg/mL TFV and 100µg/mL TFV. The 
background control signal (flow cells 1 and 3) were subtracted from the test cells 
(flow cells 2 and 4) to determine the response unit (RU) shift caused by TFV 
binding to the antibody immobilized on the flow cell. 
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Table 1. Mobile phase gradient for LC-MS detection of TFV, TFV-SH, and AMP. 
 
 
 
  
Time (Min.) Water + 0.1% Formic Acid(%) Acetonitrile + 0.1% Formic Acid(%)
0.0 100 0
0.5 95 5
1.8 92 8
3.5 90 10
6.0 88 12
6.5 30 70
9.0 30 70
9.5 100 0
14.0 100 0
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4.3 Results and Discussion 
 While the TFV-aptamer has been shown to successfully bind TFV in 
solution we wanted to characterize it on a lateral flow set-up. Using a biotinylated 
version of the aptamer we immobilized it onto streptavidin-spotted nitrocellulose 
and tested its ability to bind TFV strongly enough such that after washing with 
TBS-T the TFV will still be bound to the aptamer. After varying amounts of 
washing steps we eluted the TFV from the aptamer by boiling and characterized 
the eluted sample by LC-MS, which can quantify the amount of TFV in the eluate. 
The TFV+, nonsense, and null samples all showed undetectable levels of TFV 
after 3 washes and there was no major difference in TFV counts between the 
three samples after zero, one, or two washes (Table 2). 
 The results of the lateral flow experiment are suggestive that the aptamer 
does not perform well in a lateral flow environment. This may be due to the 
limited degrees of freedom available to the aptamer when it is immobilized on a 
surface like nitrocellulose. Additionally, without a significant spacer sequence 
between the biotin modification and the binding sequence of the aptamer we can 
expect steric hindrance to limit the ability of the aptamer to fold into the proper 
secondary structure for TFV binding. 
 We next investigated how the aptamer performs with a spacer sequence 
and when it is characterized by SPR. SPR is a gold standard method to 
characterize aptamer binding events and is capable of detecting aptamer binding 
to small molecules78–80. In short, SPR can monitor binding events occurring on 
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the SPR chip’s surface through the change in the angle of reflection of a surface 
plasmon that is incident on the chip. In addition to adding a spacer sequence to 
the aptamer we investigated whether a 3’ biotin-modified or 5’ biotin-modified 
aptamer would produce better binding results. 
 The SPR results in Figure 20 show that after 5 minute pulses of TFV 
followed by 5 minute pulses of buffer there is no overall change in the RU for 
either aptamer which is suggestive that there is no stable TFV binding occurring 
on the surface. Even when the concentration of TFV is increased there is no 
noticeable change in RU after the 5 minute wash. For the 100µg/mL TFV sample 
the large drop in signal is attributable to buffer effects due to the change in buffer 
composition when 1mg/mL TFV in PBS alone is diluted 10x into the Running 
Buffer which contains Tween-20 and MgCl2 to generate the 100µg/mL sample. 
When the wash pulse goes over the chip the signal is immediately restored to the 
original RU range since the buffer composition is restored. 
 The results of LC-MS and SPR are indicative that the aptamer did not 
function well enough when it is immobilized on a surface. As such we decided to 
proceed with raising an antibody against TFV and see if it could be used in a 
lateral flow format. While we proceeded with raising an antibody we do not 
believe that the aptamer is wholly inappropriate for lateral flow applications. 
Different modifications to the aptamer or devising a scheme that doesn’t require 
aptamer immobilization are both potential ways to improve its lateral flow 
performance. 
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Washes TFV+ Nonsense NULL 
4 0 0 0 
3 0 0 0 
2 3398 621 1995 
1 45775 53808 58942 
0 841487 893762 729666 
 
Table 2. Mass Spectrometry counts (via LC-MS) of TFV molecules after lateral 
flow incubation experiment with immobilized TFV aptamer on nitrocellulose. 
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Figure 20. SPR results of 3’-biotin-spacer-TFV aptamer and 5’-biotin-spacer-TFV 
aptamer.  
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Chapter 5: A Competitive Lateral Flow Assay for the Detection of Tenofovir 
Using a Polyclonal Anti-Tenofovir Antibody 
 
This chapter focuses on Aim 3 of my thesis work. The goal of this work was 
to develop a detection method of TFV in urine using a lateral flow assay. The assay 
is antibody-based and after raising polyclonal antibodies in rabbits we were able 
to design multiple competitive assays for the detection of TFV in urine. TFV-based 
drugs are one of the main components in both PrEP and HAART and this assay 
will allow for the direct measurement of the drug in resource-limited areas where 
traditional characterization equipment such as HPLC is not readily available. 
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5.1 Significance 
 Tenofovir (TFV) has become a cornerstone of HIV treatment since its 
approval for use in 2001 as tenofovir disoproxil fumarate (TDF). In 2015 the World 
Health Organization maintained its recommendation that TDF, which is 
metabolized into TFV in vivo, be part of the preferred first-line regimen for 
antiretroviral therapy to treat HIV patients81. In addition, the WHO recommends 
pre-exposure prophylaxis (PrEP) therapies containing TFV-derived medications 
be deployed to prevent the transmission of the virus among high-risk populations 
in both high- and low-resource settings82. As a result of these recommendations 
and the development of new formulations, such as tenofovir alafenamide (TAF), 
TFV will likely remain one of the most important tools for the treatment and 
prevention of HIV. 
The number of people accessing antiretroviral medications to manage their 
HIV infections has risen to over 18 million worldwide as of June 201683. Around 10 
million of these people are on treatment regimens containing TFV84. With the 
increasing accessibility and efficacy of these medications it becomes more 
important to ensure that drug regimens are being properly managed by HIV 
patients. Mismanagement of HIV drug regimens routinely results in a heightened 
risk of transmission, decreased patient health and quality of life, and an increase 
in the incidence of HIV drug resistance85. The WHO cites poor adherence as the 
main reason for suboptimal clinical benefits managing chronic illnesses such as 
HIV/AIDS86. Poor adherence habits have already resulted in a large growth in TFV-
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resistant HIV strains that threaten to diminish the effectiveness of one of the 
current pillars of HIV treatment87. As a result it is critical that clinicians monitor the 
adherence of HIV patients to their prescribed treatment regimens. 
To manage HIV infections and keep viral loads low patients must be at least 
80–95% adherent to their antiretroviral treatments88–91. Studies have shown that 
many populations of patients do not demonstrate adequate adherence rates7,92,93. 
There are many factors that affect patients and diminish their adherence rates: 
complexity of regimen, side effects, and patient psychological factors among 
others94–98. Fortunately, there are many intervention options available that have 
shown to improve patience adherence behaviors and health outcomes99. 
Current methods for tracking patience adherence behaviors are mostly 
indirect such as pill counting, electronic drug monitoring, and patient self-
reporting85. Pill counting and electronic monitoring are limited in their deployment 
and self-reporting, the most widely used method, is prone to overestimation100,101. 
Current direct methods to measure drug levels in patient samples generally require 
expensive equipment102 that is not easily accessible in resource-limited settings 
where the need is greatest. 
We report in the current work the first antibody-based direct measurement 
of TFV in urine. Using both a competitive HRP-based dot blot assay and a gold 
nanoparticle-based competitive lateral flow strip assay we have detected the 
presence of TFV in spiked urine samples at clinically relevant concentrations. This 
will facilitate objective monitoring of HIV adherence habits in all settings without 
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the need for expensive equipment or long turnaround times allowing clinicians to 
intervene in cases of noncompliance and improve overall patient outcomes. 
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5.2 Methods 
Materials 
TFV was purchased from Ark Pharm, Inc. Bovine serum albumin (BSA), 
keyhole limpet hemocyanin (KLH), sulfosuccinimidyl 4-(N-
maleimidomethyl)cyclohexane-1-carboxylate (sulfo-SMCC), 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC), Pierce Protein G agarose beads, 
CarboxyLink Coupling Gel, Whatman chromatography paper, and pico 
chemiluminescent substrate were purchased from ThermoFisher. Amersham 
Protran nitrocellulose was purchased from GE Healthcare Life Sciences. Anti-
rabbit antibody conjugated to horseradish peroxidase (HRP) was purchased from 
GE Healthcare. Goat anti-rabbit antibody was purchased from Abcam. N,N’-
Dicyclohexylcarbodiimide (DCC), pyridine, 3-mercapto-1-propanol, silica gel 
Davisil grade 643, Hi-Flow Plus HF180 nitrocellulose sheets, adenosine 
monophosphate, Surine negative urine control, Tween 20, sucrose, adenosine 
monophosphate (AMP), and all solvent and buffers were purchased from Sigma-
Aldrich. 40nm InnovaCoat Gold Conjugation Kit was purchased from Innova 
Biosciences. 
 
Synthesis of tenofovir-thiol hapten 
The synthesis of tenofovir-thiol (TFV-SH) slightly modified the protocol of 
Varal et al.103 for the esterification of the tenofovir phosphonate group. In short, 
270mg of TFV and 389mg of DCC were measured into a round-bottom flask to 
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which 10mL of dry pyridine and 100µL of 3-mercapto-1-propanol was added. The 
mixture was stirred under argon and refluxed for 18–24 hours. The solution was 
dried by rotary evaporation and dissolved in 10mL of a 1:1 
dichloromethane:methanol mixture. The solution was filtered and concentrated by 
rotary evaporation. Flash chromatography through a short silica gel column was 
performed on the concentrate. In short, a thin column (1cm column length is 
approximately 1mL of volume) was used and 3–4g of silica (Davisil grade 643) was 
suspended as a slurry in dichloromethane and poured into the column. The elution 
of the column was achieved by a gradient from 0% methanol to 40% methanol in 
dichloromethane. The fractions of interest were dried by rotary evaporation 
followed by high vacuum overnight. The presence of TFV-SH was confirmed by 
liquid chromatography–mass spectrometry (LC-MS). 
 
LC-MS characterization 
LC-MS measurements were taken on an Agilent 1100 series LC/MSD with 
a Cortecs C18 column (90Å, 2.7 µm, 4.6 mm X 150 mm) from Waters. Samples 
were dissolved in a solution of 975µL 0.6% trifluoroacetic acid in water and 25µL 
methanol. 20µL of sample was injected into a gradient mobile phase outlined in 
Table 1 at a flowrate of 0.6mL/min into the column equilibrated at 45°C and passed 
through the mass spectrometer set for positive polarity electrospray ionization 
(ESI+) at a range of 100–1500 m/z. 
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KLH-TFV and BSA-TFV conjugation 
20mg of BSA and 20mg of KLH were each dissolved in 2mL of phosphate 
buffer saline (PBS). To each protein solution 4mL of 5mg/mL sulfo-SMCC in PBS 
was added. The samples were incubated for 1 hour at room temperature while 
rotating before being desalted into PBS. 50mg of TFV-SH was dissolved in 500µL 
methanol and added to each sample before being incubated 2 hours at room 
temperature while rotating. The samples were desalted into PBS. About 300µL of 
the BSA-TFV sample was then desalted into pure water and conjugation was 
confirmed by matrix-assisted laser desorption/ionization – time of flight (MALDI-
TOF) and acrylamide gel electrophoresis. Mass measurements of BSA-TFV were 
taken in a Bruker Autoflex MALDI-TOF Mass Spectrometer with a sinapinic acid 
double layer matrix set to linear positive mode. 
 
Anti-TFV antibody development 
Antibody development was contracted out to Covance Inc. KLH-TFV was 
injected into rabbits and the serum containing anti-TFV polyclonal antibodies was 
then used for the current study. 
 
Immunoprecipitation of BSA-TFV Conjugate 
To a mixture of 250µL of 1mg/mL BSA and 250L of 10µg/mL diluted BSA-
TFV conjugate 1µL of serum was added and incubated overnight at 4°C (+IP 
sample). A no serum control was prepared as well (-IP sample). 20µL of the 
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sample was set aside as the “Total” sample. 20µL Protein-G beads were added to 
each sample and incubated for 1 hour at 4°C. The samples were spun down for 1 
minute at 3000rpm and decanted. The supernatant from the -IP sample 
(“Supernatant”) was set aside. The beads were then washed and decanted four 
times with yeast lysis buffer (50mM HEPES pH 7.6, 1mM EDTA, 1% Triton X-100, 
0.1% sodium deoxycho-late, 140mM NaCl), with the third wash being with a high 
salt yeast lysis buffer (500mM NaCl). The beads were heat eluted and Western 
blotting was performed with anti-TFV primary antibody and anti-rabbit HRP 
secondary antibody. Chemiluminescent photographs were taken by a VersaDoc 
Imaging Model 4000 system from BioRad. 
 
Immunoprecipitation of TFV by anti-TFV antibody 
Two samples were prepared containing a mixture of 100µL of 50µg/mL TFV 
and 100µL of 1mg/mL AMP. To one tube 375µL of anti-TFV serum (+IP) was 
added and to the other 375µL of PBS (-IP). The samples were incubated while 
rotating at 4°C overnight. 300µL of Protein G bead suspension was added to the 
samples and further incubated at 4°C for 1 hour. The samples were spun down for 
1 minute at 3000rpm and decanted. The supernatant from the (-IP) sample (-IPsup) 
was set aside. The beads were then washed and decanted four times with yeast 
lysis buffer (50mM HEPES pH 7.6, 1mM EDTA, 1% Triton X-100, 0.1% sodium 
deoxycholate, 140mM NaCl), with the third wash being with a high salt yeast lysis 
buffer (500mM NaCl). The beads were then heat eluted for 5 minutes at 95°C into 
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100µL of TE buffer. The supernatant was set aside and heat elution was repeated 
to give a total volume of 200µL of supernatant per sample. The supernatants were 
then extracted by phenol:chloroform:isoamyl alcohol and the top aqueous phase 
kept in order to remove proteins. A second chloroform extraction was performed 
to remove as much phenol as possible from the upper aqueous phase. The 
samples were then tested by LC-MS to confirm the selective immunoprecipitation 
of TFV by the anti-TFV polyclonal antibody. 
 
Competitive Dot Blot Assay 
Nitrocellulose strips were cut to dimensions of approximately 7mm by 
25mm. BSA-TFV solution in PBS was diluted down to either 1µg/mL or 100ng/mL 
representing about a 1000-fold or 10,000-fold dilution factor. The strips were then 
spotted 3 times with 1uL of diluted BSA-TFV and allowed to dry. The strips were 
blocked with 5% milk in tris-buffered saline with Tween 20 (TBS-T) for 30 minutes 
and washed three times with TBS-T. Samples of TFV were prepared at varying 
concentrations between 1ng/mL and 1µg/mL in either TBS-T or urine alongside a 
no TFV control sample. Anti-TFV polyclonal antibody was added to the TFV 
samples at a dilution of 1:50,000 and incubated at room temperature while rotating 
for at least 1 hour. The strips were incubated in the spiked urine or TBS-T solutions 
of TFV and anti-TFV polyclonal antibody at room temperature while rotating for 1 
hour and washed three times with TBS-T followed by a high-salt (500mM NaCl) 
TBS-T wash and a low-salt (50mM NaCl) TBS-T wash. The strips were then 
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incubated in a 1:8000 dilution in TBS-T of Anti-Rabbit antibody conjugated to HRP 
at room temperature while rotating for 1 hour and washed three times with TBS-T. 
The HRP was then visualized by pico chemiluminescent substrate and 
chemiluminescent photographs were taken by a VersaDoc Imaging Model 4000 
system from BioRad. 
 
Antibody Purification 
BSA-TFV protein was immobilized onto agarose beads using the 
CarboxyLink Coupling Gel protocol from ThermoFisher. In short, 2mL of gel slurry 
was packed into a disposable column and allowed to settle for 30 minutes. The 
column was washed with 10mL of 2-(N-morpholino)ethanesulfonic acid (MES) 
buffer. 1mL of approximate 1mg/mL BSA-TFV solution was desalted into MES 
buffer using a desalting column and added to the column along with 30mg EDC 
dissolved in 0.5mL MES buffer. The column was capped and the slurry was mixed 
end-over-end for 3 hours. The column was allowed to drain and washed with 1mL 
of 1M NaCl. The presence of protein in the flow-through was tested by Bradford 
assay against a BSA-TFV control sample to confirm protein remained on the 
beads. The column was washed with 5–10mL of 1M NaCl then equilibrated with 
6mL PBS. 500µL of serum was added to the column which was then capped and 
allowed to incubate for 1 hour at room temperature. The column was then washed 
with 12mL of PBS and eluted with 8mL of 100mM glycine buffer pH 3.0. Fractions 
were collected and immediately neutralized by addition of 100µL 1M Tris pH 7.5 
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buffer. Flow-through, wash, and elution fractions were checked for protein by 
Bradford assay. Elution fractions containing antibody were pooled and desalted 
into PBS buffer using a desalting column. The presence of purified antibody was 
checked by acrylamide gel electrophoresis and functionality of the antibody was 
checked by immunoprecipitation. 
 
Gold Nanoparticle Conjugation 
Conjugation of purified antibody onto gold nanoparticles was performed 
using an InnovaCoat Gold Conjugation Kit from Innova Biosciences. Briefly, 
purified antibody was diluted to 0.1mg/mL in the provided diluent solution. 12µL of 
diluted antibody were mixed with 42µL of the provided reaction buffer. 45µL of this 
mixture was then added to a tube of lyophilized 40nm gold nanoparticles provided 
by the kit. The nanoparticles were incubated on a rotator at room temperature for 
15 minutes. 5µL of the provided quencher solution was added and the 
nanoparticles were incubated for an additional 5 minutes. 500µL of 10x diluted 
quencher solution in water was added and the nanoparticles were spun down at 
9000g for 10 minutes and decanted. The nanoparticles were suspended in 50µL 
of 10x diluted quencher solution and stored at 4°C. 
 
Competitive Lateral Flow Assay 
Hi-Flow Plus HF180 nitrocellulose sheets were laser cut into lateral flow 
strips and chromatography paper was adhered to the strips as a waste reservoir 
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with tape. Samples of TFV were prepared at varying concentrations between 
10ng/mL and 100µg/mL in urine alongside a no TFV control sample. For each 
sample, 1µL of conjugated gold nanoparticles was added to 24µL of PBS and 80µL 
of sample was added. The mixture was allowed to incubate at room temperature 
on a rotator for at least 30 minutes. 0.3µL of anti-rabbit antibody was spotted on 
the strips as a control spot. 0.3µL of 2.5µg/mL BSA-TFV was spotted as the test 
spot on the strips upstream of the control spot. The spots were allowed to dry and 
another 0.3µL of BSA-TFV was spotted on top of the test spot. While the strips 
were run shortly after spotting, for long term storage the addition of sucrose to the 
BSA-TFV spots can help act as a preservative. After incubation, concentrated 
TBS-T was added to each sample such that the final Tween 20 concentration was 
0.05%. The presence of surfactant such as Tween helps the gold nanoparticles 
flow along the lateral flow strips during application of the test. The lateral flow strips 
were then added vertically into the sample tubes such that the solution ran up the 
nitrocellulose strip and into the waste reservoir via capillary action. The strips were 
incubated in solution for 25–30 minutes before being photographed with a Nikon 
DS-Ri2 camera and analyzed via ImageJ. 
 
Statistical Analysis of Sensitivity Test 
There was a statistically significant difference between groups as 
determined by one-way ANOVA (F(5,24) = 15.0, p=1.02 x 10^-6). Tukey's honestly 
significant difference post hoc test was then performed to identify which 
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concentration groups are significantly different from the no-TFV control. It was 
found that for 1µg/mL, 10µg/mL, and 100µg/mL TFV concentrations there are 
statistically significant differences from the no-TFV control. 
 
Lateral Flow Assay Specificity Test 
The protocol is the same as the competitive lateral flow assay. Solutions of 
TFV, AZT, Abcavir, AMP, and adenine were made at concentrations of 100µg/mL 
alongside a urine only control sample. 
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5.3 Results 
Generation of Rabbit anti-TFV polyclonal antibody 
To raise an antibody against TFV the molecule first had to be attached to 
an immunogenic protein prior to rabbit immunization. In order to accomplish this 
the TFV molecule had to be modified to contain a reactive side group for 
conjugation. We chose to add a thiol group to the phosphonate group of TFV 
utilizing a synthetic pathway that is similar to how TFV is converted to TDF103,104. 
One of the steps in converting TFV into TDF involves reacting TFV with alcohols 
to add more water-soluble side groups onto the TFV phosphonate. In this work we 
reacted TFV with mercapto-alcohols in order to produce thiol-modified TFV 
molecules (TFV-SH) as shown in Figure 21.  
After reacting TFV (287MW) with 3-mercapto-1-propanol (92MW) the LC-
MS data in Figure 22a confirms the presence of TFV-SH.  The synchronized 
increase in the UV absorbance at 254nm and the spike in counts by the mass 
spectrometer of 362MW species at 8.4 minutes demonstrates the existence of 
TFV-SH. The combination of TFV and 3-mercapto-1-propanol was expected to 
generate a mass spec signal at 362MW since attachment to the phosphonate side 
group was expected to liberate a water molecule. The difference in time between 
the peaks in UV absorbance and the mass spectrometry counts is the time it takes 
the sample to move from the UV detector to the mass spectrometer. 
Once TFV-SH was synthesized we attached the molecule to KLH and BSA 
by adding a maleimide side group to the proteins and then conjugating the thiol 
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group of TFV-SH to the maleimide as outlined above. The increase in molecular 
weight of the BSA molecule is demonstrated by MALDI (Figure 22b) and confirms 
successful conjugation of TFV-SH to the proteins. KLH-TFV conjugate was then 
injected into rabbits to generate polyclonal antibodies against TFV. 
Serum from the KLH-TFV immunized rabbits was analyzed to confirm the 
presence of TFV-sensitive antibodies. First, traditional western blotting and 
immunoprecipitation experiments were done to confirm the specific and sensitive 
antibody binding of the polyclonal antibody to BSA-TFV conjugates (Figure 23). 
While these successful tests, especially the successful immunoprecipitation of 
BSA-TFV in the presence of BSA and whole cell lysate, were highly suggestive of 
the presence of TFV-binding polyclonal antibodies they did not demonstrate direct 
binding of the antibody to native, unmodified TFV. However, since TFV is a small 
molecule both western blotting and traditional immunoprecipitation experiments 
would not be appropriate. As such, we performed a modified immunoprecipitation 
protocol as described above. In short, rather than transferring the 
immunoprecipitated sample to a gel for western blotting we removed proteins from 
the sample with a phenol:chloroform:isoamyl alcohol purification and analyzed the 
resulting solution with LC-MS. The confirmed presence of TFV in this sample 
(Figure 22c) demonstrates the successful generation of TFV-sensitive polyclonal 
antibodies. The corresponding absence of AMP, which is a nucleotide analogue of 
TFV and was present at a 20x higher concentration than TFV in the initial 
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immunoprecipitation sample (Figure 22c inset), also establishes the high 
specificity the antibody has to TFV. 
 
Detection of TFV by Competitive Dot Blot Assay 
After the initial validation of the anti-TFV antibody we performed a 
nitrocellulose-based competitive dot blot assay to detect the presence of TFV in 
spiked urine samples (Figure 24). Spiked urine samples with varying amounts of 
TFV were incubated with the anti-TFV antibody and nitrocellulose strips were 
spotted with BSA-TFV. Since we have established that the anti-TFV antibody is 
sensitive to both molecules we wanted to show that after incubation with TFV the 
antibody would be unable to bind the BSA-TFV that was immobilized on the 
surface. The results of the dot blot assay in Figure 25 demonstrates the validity of 
deploying a competitive assay for the detection of TFV. The assay is able to detect 
TFV at a concentration as low as 35nM in urine (about 10ng/mL) using an HRP-
coupled secondary antibody. Additionally, the success of the assay in a complex 
solution such as urine further indicates good specificity of the antibody to TFV. The 
successful detection of TFV in spiked urine samples using a competitive dot blot 
assay suggests that the anti-TFV antibody is suitable for use in a lateral flow 
device. 
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Detection of TFV by a Gold-Based Lateral Flow Strip 
Translation of the dot blot assay into a lateral flow device required 
immobilization of the anti-TFV antibody to gold nanoparticles. First, the serum was 
processed using affinity purification to isolate antibodies that bound BSA-TFV and 
validated by immunoprecipitation (Figure 26) to confirm the purified antibody was 
still functional. The antibody was then conjugated onto 40nm gold nanoparticles 
for use in the lateral flow assay. 
The lateral flow assay is based on the same principles as the dot blot assay 
(Figure 27a and Figure 27b). Anti-TFV antibody conjugated to gold beads was 
incubated with TFV-spiked urine samples and allowed to flow over a nitrocellulose 
strip containing spotted BSA-TFV followed by anti-rabbit antibody spotted 
downstream. The results of the assay in Figure 27c, Figure 28, and Figure 29 show 
sensitive, statistically significant, and specific detection of TFV in spiked urine 
samples with a sensitivity as low as 1µg/mL. 
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Figure 21. TFV-SH Synthesis 
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Figure 22. A) LC-MS characterization of purified TFV-SH synthesis product. (top) 
UV Absorbance at 254nm. (bottom) Mass Spec signal of 362 MW. B) MALDI 
measurements of BSA-Maleimide intermediate and BSA-TFV conjugate. BSA has 
a MW of 66,463. C) LC-MS characterization of TFV immunoprecipitation and 
(inset) pre-immunoprecipitation sample. 
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Figure 23. Immunoprecipitation of BSA-TFV by anti-TFV polyclonal antibody. 
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Figure 24. Schematic of competitive dot blot assay using BSA-TFV and anti-TFV 
polyclonal antibody. 
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Figure 25. i) BSA-TFV spotting on nitrocellulose strips. ii) Competitive dot blot 
assay performed on BSA-TFV spotted nitrocellulose strips. Decrease in signal 
corresponds to an increase in TFV urinary concentration. 
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Figure 26. Immunoprecipitation of BSA-TFV by affinity column purified anti-TFV 
polyclonal antibody. 
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Figure 27. A) Schematic of competitive gold-based lateral flow assay. B) Expected 
output of competitive gold-based lateral flow assay. As the amount of TFV 
increases in the sample the test spot intensity decreases. C) Sensitivity test of 
competitive gold-based lateral flow assay in TFV-spiked urine samples. 
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Figure 28. Competitive gold-based lateral flow assay statistical analysis of 
sensitivity test. Strips were imaged and processed by ImageJ to get background-
normalized intensity measurements of test spots for varying concentrations of TFV 
spiked into urine. Points with asterisks are statistically significant compared to the 
no-TFV control strips (N=5). The gray band visualizes the range of intensity signal 
from the control spots. 
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Figure 29. Specificity test of gold-based lateral flow assay. Top spot is the control 
spot and the lower spot is the test spot. The bottom section is unspotted. The lower 
relative intensity of the TFV test spot compared to the control test spot 
demonstrates a positive result while all other test spots are negative due to their 
similar relative intensity compared to the control test spot. 
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5.4 Discussion 
Raising and deploying an antibody against a small molecule presents 
several challenges. Initially the desired antigen is often not enough on its own to 
generate the immune response necessary in the host for antibody development. 
As a result the desired antigen, referred to as a hapten, often must be conjugated 
onto a carrier protein to coax an immune response from the host105–107.  
Another challenge in the development of small molecule-sensitive 
antibodies is characterization of the host serum after immunization. For protein 
targets gel electrophoresis is a common technique to isolate and visualize 
antibody-protein interactions. However, since small molecules are not privy to gel 
electrophoresis other techniques such as quartz crystal microbalance108, surface 
plasmon resonance109, and mass spectrometry110 must be used to confirm 
antibody-target binding.  
Additionally, small molecule targets present a difficult challenge to standard 
deployment methods in lateral flow setups. The most common lateral flow method 
involving antibodies relies on sandwich assays to both capture and visualize the 
same molecule using two antibodies, one immobilized to the lateral flow substrate 
and the other linked to a visualization moiety. This method relies on large targets 
such as peptides and proteins having multiple antibody-binding sites allowing both 
antibodies to bind. Small molecules, however, often only have a single antibody-
binding site and this precludes the possibility of using a sandwich assay. For small 
molecules competitive ELISA assays have become a common technique for small 
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molecule detection111–113. In this work we have been able to overcome many of 
these challenges to develop an assay for the detection of TFV. 
Attaching TFV onto a carrier protein required modification of the molecule 
because the molecule was not reactive enough for direct conjugation. We chose 
to add a thiol group onto the TFV molecule because the use of Sulfo-SMCC to link 
thiol-containing molecules to proteins is efficient and well characterized114. Figure 
22b demonstrates how the two-step reaction first added the Sulfo-SMCC to BSA 
through the reaction of primary amines (from lysine residues) with NHS on the 
Sulfo-SMCC then added the TFV-SH molecule through the reaction of the thiol 
group to the maleimide of the Sulfo-SMCC. It is important to note that the MALDI 
data presented in Figure 22b shows the results of TFV conjugation onto BSA, not 
the results of conjugation onto KLH. KLH is too large of a protein (390kDa) for 
convenient MALDI measurements and therefore BSA-TFV was measured and we 
assumed that the KLH-TFV reaction proceeded with similar efficiency. 
After immunization the serum was analyzed to confirm that the polyclonal 
antibody generated was both sensitive and specific to TFV. Figures 23 and Figure 
22d show that the anti-TFV antibody is sensitive and specific to BSA-TFV and TFV, 
respectively. The immunoprecipitations were done in the presence of excess 
whole cell lysate or AMP to demonstrate the specificity of the antibody. AMP was 
chosen because of the structural similarities to TFV and because adenosine in 
general may be present in patient samples that would be screened by the anti-TFV 
antibody. Since TFV samples cannot be characterized by standard western 
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blotting we eluted the protein-G beads and purified the sample using 
phenol:chloroform:isoamyl alcohol mixture before LC-MS measurements were 
taken to demonstrate the sensitivity and specificity of the antibody to TFV. 
With the anti-TFV antibody in hand we then proceeded to develop a 
competitive assay to detect TFV. Similar to other competitive ELISAs, the principle 
of the assay is that as the concentration of TFV in the sample increases and more 
of the anti-TFV antibody is bound to free floating TFV less of the anti-TFV antibody 
is unbound and available to bind to the spots of BSA-TFV immobilized onto a 
nitrocellulose substrate. The result is that when incubated in anti-rabbit HRP 
secondary antibody the chemiluminescent signal of these spots is indirectly 
proportional to the amount of free TFV in the original sample. 
In this work we have chosen to study TFV-spiked urine as our biological 
sample. Urine provides several advantages in monitoring TFV adherence. Urine 
tests are non-invasive compared to assays that measure plasma. For patients on 
TFV regimens the urinary concentration of TFV is usually over 100x more 
concentrated than the plasma115 concentration. Also, urine does not require any 
sample preparation before testing it with our assay. 
Figure 25 validates that the competitive assay works with spiked urine 
samples and that TFV can be detected at concentrations as low as 10ng/mL. It is 
interesting to note that the BSA-TFV protein spots required dilution of several 
orders of magnitude before being spotted onto the nitrocellulose strips. When 
undiluted BSA-TFV (~1mg/mL) is spotted onto the strips the assay can no longer 
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differentiate between TFV-positive and TFV-negative samples (data not shown). 
We do not know why spotted protein needs to be diluted down to a concentration 
as low as 1µg/mL for the assay to perform as desired, but we speculate that an 
overabundance of protein on the nitrocellulose spots may increase non-specific 
binding of either the anti-TFV or anti-rabbit HRP antibodies resulting in high non-
specific signal. 
The assay to detect TFV in urine needs to be sensitive enough to identify 
patients that are properly adhering to their regimens and those who are not. For a 
patient taking 300mg TDF daily the urine concentration of TFV is around 
23µg/mL115. When 300mg of TFV is ingested only once the concentration of TFV 
in urine after 24–72 hours is generally around 1–10µg/mL116. The increased use 
of TAF as an alternative to TDF in drug regimens will shift these sensitivity 
windows. TAF is dosed at 25mg per day and thus results in about a 10x decrease 
in TFV plasma concentrations117. Assuming this also correlates to a 10x decrease 
in TFV urine concentrations it would suggest that daily ingestion of 25mg TAF 
would result in about 2.3µg/mL of TFV in urine as a gross estimate. The 24–72 
hour TFV urine concentration after a single 25mg dose of TAF would similarly be 
estimated to be around 0.1–1µg/mL. 
All of these pertinent concentration windows are detectable using the 
competitive dot blot assay which has a sensitivity as low as 10ng/mL. It is relevant, 
however, to consider that 10ng/mL may be too sensitive for practical use. 
According to recent work by Koenig et al. an isolated TFV dose would result in 
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urinary TFV concentrations above 10ng/mL for the next week116. A strength of this 
assay is that the effective sensitivity can be tuned by changing the amount of anti-
TFV antibody that is incubated with a sample. Increasing the amount of antibody 
that is incubated with the sample would necessarily increase the amount of TFV 
required to prevent antibody binding to the spotted BSA-TFV thus allowing the 
assay sensitivity to be tuned to selectively detect desired concentration windows. 
For a sensitivity of 10ng/mL the dot blot assay required a 50,000x dilution factor of 
the raw serum into the sample. Theoretically, a 500x or 50x dilution factor of the 
serum into the sample would result in a sensitivity limit between 1µg/mL and 
10µg/mL. 
While the dot blot assay is flexible and sensitive there are limitations that 
hinder potential deployment in the clinic especially in resource-limited settings 
where the need is greatest. The dot blot assay protocol requires many steps 
including nitrocellulose blocking and membrane incubations that increase the time 
required to get a result. Also, chemiluminescent measurements generally require 
some capital investment by the clinic in equipment and training to get visual results. 
To address these concerns and develop an assay that is more suitable for 
deployment we designed a gold-based lateral flow strip for faster and more 
affordable TFV adherence monitoring. 
The gold-based lateral flow strip assay generates a clear colorimetric 
readout requiring less time, training, and equipment than the HRP-based dot blot 
assay. As higher concentrations of TFV samples are assayed the signal strength 
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of the BSA-TFV test spot decreases as the anti-rabbit antibody control spot 
remains relatively constant. As shown in Figure 27b and Figure 27c, a negative 
test result will generate two spots of similar intensity while a positive test result will 
generate a test spot that is markedly lighter than the control spot. The sensitivity 
down to 1µg/mL and the high specificity of the anti-TFV antibody suggests the 
lateral flow assay is appropriate for assaying urine samples of HIV patients 
prescribed TFV-containing drug regimens. The speed and simplicity of the lateral 
flow assay shows a marked improvement over the HRP-based assay for potential 
deployment in resource-limited settings. 
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5.5 Conclusions 
The simplicity of the assay suggests that if antibodies against other 
medications can be raised then the scope of which drug metabolites can be 
measured by this assay could broaden further. The assay is also flexible enough 
to be immediately paired up with other low-cost monitoring devices for drug 
regimens in the treatment of diseases that are commonly co-infected with HIV such 
as hepatitis118,119 and tuberculosis120. Along with multiplexing, further work will 
address increasing the contrast between TFV-negative and TFV-positive assay 
results to potentially increase sensitivity or altering the design such that the 
appearance and increased intensity of the test spot will indicate a TFV-positive 
rather than a TFV-negative result. 
As the use of TFV-containing drugs continues to expand in the treatment 
and prevention of HIV so too does the need increase for accurate monitoring 
techniques in order to improve patient outcomes and reduce the proliferation of 
TFV-resistant HIV strains. In this work, we have developed an anti-TFV antibody 
and a competitive gold-based lateral flow assay to test urine as an objective tool 
for monitoring patient adherence habits. The assay does not need an external 
power source, it is affordable to develop and deploy in both resource-rich and 
resource-limited settings, and it non-invasively gives an accurate colorimetric 
output measuring clinically relevant concentrations of TFV in urine in less than 1 
hour. 
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Chapter 6: Conclusions and Future Directions 
  
Patient adherence monitoring is a key component in the continued 
management of HIV and the mitigation of its negative consequences. 
Unfortunately, HIV treatment regimens require near perfect adherence (between 
80–95%) to prescribed dosing schedules. The negative consequences of failing to 
meet this standard are severe. Drug resistant HIV can develop that renders the 
drug ineffective. Worse still, this drug resistant strain can spread and lower the 
overall efficacy of the most important HIV medications87. The health and financial 
costs of low adherence are prohibitive as new drugs are costly to produce and 
patient outcomes worsen. To combat this, clinicians must monitor their patients’ 
adherence habits to intervene in cases of low adherence and prevent negative 
health outcomes. Fortunately, it has been shown that clinician intervention in cases 
of low adherence often result in restored adherence patterns5,99. 
The goal of this thesis was to develop new direct measurement tools for 
clinicians to monitor patient adherence habits to HIV medications. To achieve this, 
we developed two paper-based detection methods for azidothymidine, we 
discovered that the 110-year old Wheeler and Johnson test can be applied to the 
detection of both lamivudine and emtricitabine, and we created the first antibody-
based lateral flow detection method for tenofovir, a keystone drug for both PrEP 
and HAART. All of these methods have been successfully applied to urine, which 
can be collected and assayed non-invasively and with minimal sample preparation, 
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and can be deployed in resource-limited settings without the need for expensive 
equipment. 
The success of these assays opens many avenues for future work. The 
potential of the click chemistry protocol for the AZT dipstick test can be explored 
to test for other azide containing molecules such as Efavirenz, Nikovir, and even 
sodium azide. The Wheeler and Johnson test can be studied more thoroughly to 
identify why it can detect a cytidine analogue such as 3TC and FTC but not the 
nucleotide itself. The proposed 3TC and FTC test can also be improved by 
developing a reliable method to concentrate urine samples, and by finding a way 
to safely deploy the assay in a point-of-care format.  
While the fundamental principles of the assays for AZT, 3TC, and FTC are 
specific only to those drugs, the principles of the TFV lateral flow assay can 
conceivably be generalized for the detection of other current and future small 
molecule targets. If other drug metabolites can be conjugated to immunogenic 
proteins as haptens then antibodies sensitive to those molecules can be raised 
deployed in this assay. The TFV lateral flow assay could also be multiplexed to 
other assays to monitor drug adherence to treatments for common HIV-
coinfections such as tuberculosis and hepatitis.  
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